Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
about
Role of bile acids in the regulation of the metabolic pathwaysPathophysiological role of host microbiota in the development of obesityTreatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directionsDiet, Microbiota, Obesity, and NAFLD: A Dangerous QuartetGut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of MetabolomicsRole of bile acids in carcinogenesis of pancreatic cancer: An old topic with new perspective.Fatty liver diseases, bile acids, and FXRCeramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosisAmerican Diabetes Association and JDRF Research Symposium: Diabetes and the MicrobiomeFarnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls Hepatic Lipid Metabolismβ-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue.Gender Differences in Bile Acids and Microbiota in Relationship with Gender Dissimilarity in Steatosis Induced by Diet and FXR Inactivation.Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome.Persistent Organic Pollutants Modify Gut Microbiota-Host Metabolic Homeostasis in Mice Through Aryl Hydrocarbon Receptor Activation.Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient dietPerilipin-2 Modulates Lipid Absorption and Microbiome Responses in the Mouse Intestine.Gut-liver axis, nutrition, and non-alcoholic fatty liver diseaseAntioxidant Drug Tempol Promotes Functional Metabolic Changes in the Gut MicrobiotaComparative experimental investigation on the efficacy of mono- and multiprobiotic strains in non-alcoholic fatty liver disease preventionDiet-microbiota interactions as moderators of human metabolism.An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease.Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota.Personalized microbiome-based approaches to metabolic syndrome management and prevention.Intestinal FXR: A New Therapeutic Target for Nonalcoholic Fatty Liver Disease.An Intestinal Farnesoid X Receptor-Ceramide Signaling Axis Modulates Hepatic Gluconeogenesis in Mice.Gut Microbiota in Cardiovascular Health and Disease.Sex-Specific Differences in Hepatic Fat Oxidation and Synthesis May Explain the Higher Propensity for NAFLD in Men.Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunctionNutritional modulation of gut microbiota - the impact on metabolic disease pathophysiologyTryptophan-induced pathogenesis of breast cancerNon-alcoholic fatty liver and the gut microbiota.Antibiotic effects on gut microbiota and metabolism are host dependent.Xenobiotic Receptor-Mediated Regulation of Intestinal Barrier Function and Innate Immunity.Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.Interactions of Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease: Possible Mechanisms and Clinical Impact.Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application.Recent advances in mouse models of obesity- and nonalcoholic steatohepatitis-associated hepatocarcinogenesis.Molecular basis of alcoholic fatty liver disease: From incidence to treatment.Western Diet-Induced Dysbiosis in Farnesoid X Receptor Knockout Mice Causes Persistent Hepatic Inflammation after Antibiotic Treatment.Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease.
P2860
Q26738976-4214D160-F60C-4D22-AA5A-34C9A4701812Q26750893-2FF077D3-0CF0-4952-AD87-AF6E39F42A94Q26751258-8C55B97A-7141-43F9-9CC9-1586C7502335Q26752614-9A3DD6F1-33A6-4191-9ADC-902BB9A37AB5Q26753047-82CE5A81-3287-4879-A812-AA2092F8C047Q27693345-05CE8464-7136-4CC6-A0D7-EDAB384D3B1EQ28068199-3B031072-4D55-4CAD-87AE-14A9D978251BQ28547365-9DFD07C6-610C-4050-A916-4942C24BC68BQ28602363-D1453A68-7D7A-4DC6-90BD-45A9162131BEQ28821039-383DEE6F-A595-4527-B845-85E44DAAC587Q33578966-1F290977-5565-49CA-8C18-6457CDBDB5ADQ33687018-18909004-EEB5-4FBE-B93B-D424640AB214Q33711736-7B9B72F1-EE84-4E04-B0BB-484171979DA0Q35576758-309E9D29-5319-4659-9E4B-94A3BD79681AQ35613153-3A0702D4-C741-4114-AC33-6C2C91CDE6D2Q35683242-4E8F1958-594D-45EE-A417-EDB1E3D7BAF8Q35685083-1F52D863-744E-4A51-880D-8749BAA11A7AQ35876212-F869B464-D64D-40E5-91BC-F51B6F1B00C3Q35956826-CA9C7AC2-0D1C-4EB1-AB96-F66CB6A28CDFQ36069065-F95CE5C9-4A12-4403-B2E1-90886EFC34CBQ36136449-528E07B2-D75A-4E68-9E70-F26ADFCDEF2DQ36148926-470D4EA4-B170-4767-B15B-C307F8E19093Q36175953-385852A0-3E47-4803-83A4-C8D6A148A341Q36245966-7B315077-3421-4440-8306-53C2BDE18A90Q36287039-0FFD0196-3A37-4990-A5CB-D3E34409B832Q36329055-0DEE3307-7ADF-4015-B640-5A686EE63811Q36339964-7A7C639B-1AFB-4B31-BB11-77D773D10C94Q36379436-C6CE858B-6EE8-497C-8B9C-132D97281C69Q36590565-6740A3F7-5749-4A02-A754-48BDC2EE1E73Q36612713-4CF5A7DD-7C5E-49BE-9133-FBF6229633A8Q37215934-BEA0188D-E028-42DE-9BF8-C5918643A65DQ37452266-3144B8A9-DF5B-4EA4-AA46-AD44331E11BDQ37486151-9A847AC7-3454-4C28-881F-AD1D5B83BAC6Q37538343-0B206B8C-6EF9-48E7-9D90-2F88536EFAEDQ38538187-94F5AF1C-1601-4DC3-A057-7DC0284106ADQ38541491-30BB8F82-0EB5-4E60-A5B4-82D0DA22EB1BQ38572366-B223E470-0C78-40F6-AB69-CFA7127CD579Q38595071-EBA0A137-03D3-408A-90AE-B98DC0296402Q38677715-C4E24EFE-FA38-4BD9-9871-6F6066836909Q38711424-D78F2B24-2CE4-4AEC-9B2D-140A590FD6E7
P2860
Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
@ast
Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
@en
type
label
Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
@ast
Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
@en
prefLabel
Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
@ast
Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
@en
P2093
P2860
P50
P356
P1476
Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
@en
P2093
Dhimant Desai
Frank J Gonzalez
Kristopher W Krausz
Limin Zhang
Naoki Tanaka
Robert G Nichols
Shantu G Amin
Shogo Takahashi
P2860
P304
P356
10.1172/JCI76738
P407
P577
2014-12-15T00:00:00Z